IRD vs OKTA · rev $11.0M vs P/E 84, rev $2.61B
Opus Genetics, Inc. (IRD) versus Okta Inc (OKTA) — a side-by-side from cached financials, not a winner call.
Opus Genetics, Inc. (IRD) is a biotechnology company listed on US.
Okta Inc (OKTA) is a software - infrastructure company listed on NASDAQ.
Latest reported IRD revenue for 2024-12-31 was $11.0M. Net income was -$57.5M. Revenue was down 42.3% from 2023-12-31 to 2024-12-31. IRD currently screens at market cap $35.7M.
Latest reported OKTA revenue for 2025-01-31 was $2.61B. Net income was $28.0M. Revenue was up 15.3% from 2024-01-31 to 2025-01-31. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
IRD currently screens at market cap $35.7M. OKTA currently screens at market cap $20.06B and trailing P/E 83.6.
Not investment advice. Open the IRD and OKTA stock pages for the full models.
Not investment advice.